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In the field of stem cell biology and diabetes, we and others seek to derive mature 
and functional human pancreatic β cells for disease modeling and cell replacement 
therapy. Traditionally, knowledge gathered from rodents is extended to human pancreas 
developmental biology research involving human pluripotent stem cells (hPSCs). While 
much has been learnt from rodent pancreas biology in the early steps toward Pdx1+ 
pancreatic progenitors, much less is known about the transition toward Ngn3+ pancre-
atic endocrine progenitors. Essentially, the later steps of pancreatic β cell development 
and maturation remain elusive to date. As a result, the most recent advances in the 
stem cell and diabetes field have relied upon combinatorial testing of numerous growth 
factors and chemical compounds in an arbitrary trial-and-error fashion to derive mature 
and functional human pancreatic β cells from hPSCs. Although this hit-or-miss approach 
appears to have made some headway in maturing human pancreatic β cells in  vitro, 
its underlying biology is vaguely understood. Therefore, in this mini-review, we discuss 
some of these late-stage signaling pathways that are involved in human pancreatic β 
cell differentiation and highlight our current understanding of their relevance in rodent 
pancreas biology. Our efforts here unravel several novel signaling pathways that can be 
further studied to shed light on unexplored aspects of rodent pancreas biology. New 
investigations into these signaling pathways are expected to advance our knowledge in 
human pancreas developmental biology and to aid in the translation of stem cell biology 
in the context of diabetes treatments.
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inTRODUCTiOn
In the field of stem cells and diabetes, many scientists are actively pursuing the generation of insulin-
secreting pancreatic β cells from human pluripotent stem cells (hPSCs) for β cell transplantation/
replacement and treatment of diabetes (1–3). While insights from rodent pancreas developmental 
biology has guided the generation of PDX1+ pancreatic progenitors from hPSCs, the specific 
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developmental principles thereafter remain murky. Henceforth, 
research groups have relied upon the transplantation of pancreatic 
progenitors, derived in vitro, into rodents for in vivo maturation 
(4–6). However, there has been considerable progress toward the 
generation of mature and functional human pancreatic β cells 
in vitro in the recent years. These β cells purportedly co-express 
cardinal β cell markers, such as PDX1, NKX6.1, musculoaponeu-
rotic fibrosarcoma oncogene homolog A (MAFA), prohormone-
processing enzymes, insulin, and C-peptide. Importantly, they 
are also monohormonal and glucose responsive.
Developmental biologists believe that there is much to be 
learnt from rodent developmental biology to guide hPSC-based 
generation of clinically useful cell types, such as pancreatic β cells. 
Owing to such efforts, the progression of definitive endoderm 
(DE) germ layer to PDX1+ pancreatic progenitors has been well-
explored. However, the investigations on the later steps of pancre-
atic endocrine development and β cell maturation have not been 
quite fruitful. The most substantial advances in stem cell biology 
have relied upon an arbitrary approach of iterative trial-and-error 
testing to achieve mature and functional pancreatic β cells in vitro 
(7). Therefore, several pertinent questions remain: why were we 
not able to extrapolate rodent developmental principles and apply 
them on hPSCs to derive mature and functional pancreatic β 
cells? Are there differences between rodent and human pancreas 
development that prevent such an application? In this review, we 
look at signaling pathways that have been activated or repressed 
in stem cell biology and retrospectively revisit existing knowl-
edge about rodent pancreas biology. Our efforts highlight novel 
aspects of signaling pathways that can be further investigated in 
our translational efforts for diabetes.
inHiBiTiOn OF TRAnSFORMinG 
GROwTH FACTOR-β SiGnALinG in THe 
LATeR STAGeS OF PAnCReATiC 
DiFFeRenTiATiOn
The transforming growth factor-β (TGF-β) superfamily of pro-
teins regulates pancreas development and function (8). TGF-β1, 
TGF-β2, and TGF-β3 are expressed in pancreatic epithelial cells at 
E12.5 in mice. Thereafter, they become localized in the acinar cells 
(9). TGF-β1 can promote the development of mouse pancreatic 
β cells from pancreatic buds (10). Perplexingly, it also indirectly 
inhibits the formation of mouse pancreatic epithelial cells (11). 
In tandem, TGF-β2 has been demonstrated to inhibit Hnf1β and 
Pdx1 gene expression. Hence, TGF-β can purportedly restrain 
the specification of pancreatic cell fate (12). TGF-β signaling 
effector SMAD3 can bind the Ins gene promoter to suppress its 
expression. In agreement, Smad3-deficient islets exhibit an active 
insulin signaling pathway (13). Collectively, these evidences sug-
gest the requirement to inhibit TGF-β signaling for the derivation 
of mature and functional pancreatic β cells (Figure 1A).
In 2011, Nostro et  al. used small molecule SB431542 (14), 
an Activin/TGF-β receptor antagonist, in their pancreatic dif-
ferentiation protocol. SB431542 inhibits activin receptor-like 
kinases (ALK) 4/5/7 and the downstream TGF-β/Activin/Nodal 
signaling. SB431542 treatment was demonstrated to increase 
INS gene expression and the development of C-peptide+ cells 
(15). Similarly, Cho et  al. also utilized SB431542, in the pres-
ence of retinoic acid (RA), for pancreatic differentiation (16). 
Alternatively, Schulz et al. used TGF-βRI kinase inhibitor IV to 
obtain pancreatic progenitors from CyT49 hPSCs (17). Rezania 
et al. identified that the use of 2-(3-[6-Methylpyridin-2-yl]-1H-
pyrazol-4-yl)-1,5-naphthyridine (ALK5iII) can effectively induce 
the expression of NGN3, NEUROD1, INS, and GCG transcripts 
to promote pancreatic endocrine specification (18). Rezania et al. 
further demonstrated that 1  μM ALK5iII is necessary for the 
induction of NEUROD1+ cells, but it suppressed the proportion 
of NKX6.1+ cells (4), a hallmark of functional β cells (19). Most 
recently, Rezania et  al. compared the effects of several ALK5 
inhibitors at a later phase of differentiation of hPSCs and found 
that only ALK5iII downregulated NGN3 while increasing INS, 
GCG, and SST transcripts (6). Furthermore, 10  μM ALK5iII 
induced the expression of nuclear v-maf MAFA transcript, a criti-
cal mature β cell transcription factor, in diabetic rodents (20–22). 
Rezania et al. (6) concluded that ALK5iII was the most effective 
and specific inhibitor as it inhibited ALK5 but had minimal inhi-
bition of other kinases. Similarly, Pagliuca et al. also employed 
10 μM Alk5iII to derive mature and functional human pancreatic 
β cells from hPSCs (7) (Figure 1B; Table 1).
Overall, the inhibition of ALK5/TGF-βRI with ALK5iII 
appears to be more desirable as compared to the general inhibi-
tion of TGF-β signaling via the use of SB431542. Further studies 
are certainly required to investigate the intricacies of TGF-β 
signaling during pancreas development and β cell maturation.
PROTein KinASe C SiGnALinG 
enHAnCeMenT
Protein kinase C (PKC) is a family of serine/threonine kinases 
that are involved in diverse cellular processes, including survival, 
apoptosis, cell cycle regulation, proliferation, migration, and 
differentiation (23). In maturing neonatal rat islets, PKCα was 
only found in β cells, PKCγ in α cells, and PKCϵ in δ cells (24). 
This differential expression of PKC isoenzymes (25) hints that 
PKC signaling may play a role in the functional maturation of 
pancreatic endocrine progenitors (Figure 1A).
Chen et  al. (26) was the first to demonstrate that 300  nM 
(−)-indolactam V (ILV) or PKC agonists {500  nM [(2S,5S)-
(E,E)-8-(5-(4-(trifluoromethyl)phenyl)-2,4-pentadienoylamino) 
benzolactam (TPB)] or 14 nM phorbol-12-myristate-13-acetate 
(PMA)} can efficiently increase the formation of PDX1+ pancre-
atic progenitors from hPSCs via the activation of PKC signaling. 
ILV treatment resulted in an increased gene expression of several 
pancreatic progenitor markers, including SOX9, PDX1, PTF1A, 
HNF6, and PROX1, and endocrine progenitor markers, including 
NGN3, NKX2.2, and NKX6.1. The protein expression of pancreatic 
progenitor markers FOXA2, PTF1A, HNF6, and NKX6.1 were 
increased, whereas the expression of intestinal marker CDX2 and 
liver marker AFP were suppressed (26). In addition, they also 
found that ILV and PKC agonists, TPB or PMA, can synergize 
with FGF10 signaling to promote the proliferation of PDX1+ cells 
derived from hPSCs. Interestingly, ILV treatment also works on 
FiGURe 1 | A summary of the pivotal stages of pancreatic differentiation. (A) Mammalian pancreas development based on knowledge from both rodent and 
human studies. The signaling pathways suggested to be positively regulating the differentiation process are highlighted in green, while those found to be inhibited in 
order to drive differentiation toward pancreatic lineage are shown in red. (B) An in vitro pancreatic differentiation timecourse generating β-like cells from hPSCs. The 
signaling pathways (green) and antioxidants (pink) that are positively regulating the differentiation process at each phase of development are highlighted. Stage-
specific signaling pathways that are inhibited to drive differentiation toward pancreatic lineage are shown in red. The decreasing doses of RA used during the 
differentiation process [as described by Rezania et al. (6) and Pagliuca et al. (7)] are represented by the decreasing shades of green. The differing colors co-existing 
in an aggregate illustrates the heterogeneity of cells prevalent in such a differentiation scheme. While some of the cells will transit from being endocrine progenitors 
(light orange) to Pdx1+ insulin-producing β-like cells (brown), the end-product will include an assortment of maturing endocrine cell types (represented by orange and 
light orange).
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mouse embryonic stem cells, suggesting a conservation of signal-
ing pathway in both mouse and human cells (26) (Table 1).
Subsequently, Rezania et al. (4) employed two PKC activators 
in the mid-late stage of hPSC differentiation; 50 nM TPB (safer 
profile) and phorbol 12,13-dibutyrate (PDBu) (27), demonstrating 
that the activation of PKC signaling induces the gene expression 
of pancreatic lineage markers PTF1A, NGN3, NEUROD1, and 
NKX6.1 while suppressing the expression of intestinal (CDX2) 
and liver (ALB) markers (4). This demonstrated that PKC signal-
ing enriches the development of pancreatic progenitors while 
inhibiting intestinal and hepatic lineages. Similarly, Pagliuca et al. 
used 500 nM PDBu in their pancreatic differentiation protocol 
(7) (Figure 1B; Table 1). Although these data are encouraging, 
more studies remain to be done to thoroughly clarify the role of 
PKC signaling and the specific mechanisms in the maturation of 
pancreatic endocrine progenitors.
LOweR LeveL OF ReTinOiC ACiD 
SiGnALinG AS PAnCReATiC 
DiFFeRenTiATiOn PROGReSSeS
It is well-established that RA signaling plays critical roles in 
the early and late stages of pancreas development (28). RA is a 
TABLe 1 | Summary of some novel signaling pathways perturbed during pancreatic differentiation of hPSCs.
Molecules Mechanism induction of pancreatic lineage markers Reference Humans Rodents
TGF-β inhibition SB431542 Inhibits ALK 4/5/7 Upregulates INS gene expression and C-peptide+ cells Nostro et al. (15) √
SB431542 + RA Upregulates PDX1 gene expression Cho et al. (16) √
TGF-βRI kinase inhibitor IV Induces pancreatic progenitors from hPSCs Schultz et al. (17) √
1 μM ALK5iII Inhibits ALK5 Downregulates NGN3. Upregulates NEUROD, INS, GCG, and SST transcripts
Induces Mafa transcript expression in diabetic rodents
Rezania et al. (4, 6, 18) √ √
10 μM ALK5iII Pagliuca et al. (7) √
Protein kinase C 
signaling
 300 nM ILV Activates PKC
Synergizes with 
FGF10 signaling
Upregulates gene expression of pancreatic progenitor markers SOX9, PDX1, PTF1A, 
HNF6, PROX1
Chen et al. (26) √ √
Upregulates gene expression of endocrine progenitor markers including NGN3, NKX2.2, 
and NKX6.1
500 nM TPB
14 nM PMA
Upregulates protein expression of FOXA2, PTF1A, HNF6, and NKX6.1 √
√Downregulates protein expression of endoderm markers CDX2 and AFP
50 nM TPB Activates PKC Upregulates gene expression of pancreatic lineage markers NGN3, NEUROD1, PTF1A, 
and NKX6.1
Downregulates gene expression of intestinal marker CDX2 and liver marker ALB
Rezania et al. (4) √
500 nM PDBu Pagliuca et al. (7) √
Low retinoic acid 
(RA) signaling
1–3 μM RA Activates RA 
receptors
Various √
3 nM TTNPB Schulz et al. (17) √
1 μM → 100 nM → 50 nM RA Rezania et al. (7) √
2 μM → 100 nM → 25 nM RA Pagliuca et al. (7) √
 γ-secretase/Notch 
inhibitor
DAPT Inhibits Notch 
signaling
Upregulates NGN3 mRNA and protein expression in adult islets Dror et al. (36) √ √
Upregulates NGN3 and NEUROD1 gene expression Rezania et al. (18) √
GSiXX Upregulates expression of β cell maturation genes Rezania et al. (6) √
Downregulates expression of pancreatic exocrine marker PTF1A
GSiXX + T3 Upregulates NKX6.1+insulin+GCG- β-like cells Rezania et al. (6) √
1 μM XXI Upregulates β cell gene expression Pagliuca et al. (7) √
T3 0.1 μM T3 Activates MAPK/
ERK signaling 
pathway
Induces rodent pancreatic β cell proliferation Kim et al. (42) √
1 μM T3 Upregulates expression of INS and mature β cell markers Rezania et al. (6) √
Enhances co-expression of NKX6.1 and INS protein Pagliuca et al. (7)
AXL 2 μM BGB324 (R428) Inhibits AXL Upregulates MAFA protein expression Rezania et al. (6) √
GAS6 Activates AXL Downregulates Mafa gene expression Haase et al. (48) √
Antioxidants GPx-1 Antioxidants Maintains protein expression of nuclear MAFA in diabetic rodents Harmon et al. (22) √
√
√
NAC Harmon et al. (21)
Ebselen Mahadevan et al. (20)
1–2 mM NAC Upregulates nuclear MAFA protein expression Rezania et al. (6) √
0.25 mM vitamin C Generates mature and functional human pancreatic β cells Pagliuca et al. (7) √
Betacellulin BTC Binds to ErbB-1 
and ErbB-4 
receptors to initiate 
PI3K/Akt, MAPK, 
STAT, and mTOR 
signaling pathways
Upregulates insulin secretion Dahlhoff et al. (65)  
 
 
√
√
√
√
Upregulates mRNA and protein expression of IRS-2 Oh et al. (68)
Induces Pax4 gene expression in rat islets Brun et al. (70)
Sustains PDX1 expression and induces β cell differentiation from hESCs Cho et al. (71)
10 ng/ml BTC Upregulates Pdx1 gene expression and insulin production Thowfeequ et al. (72) √
Downregulates amylase and glucagon production in mouse embryonic pancreas explants
20 ng/ml BTC Induces pancreatic differentiation Pagliuca et al. (7) √
50 ng/ml EGF Preserves cell mass Schulz et al. (17) √
BTC, Betacellulin; DAPT, N-[N-(3,5-difluorophenacetyl-l-alanyl)]-S-phenylglycine t-butyl ester; GPx-1, glutathione peroxidase-1; GSiXX, γ secretase inhibitor XX; ILV, (−)-indolactam V; NAC, N-acetylcysteine; PDBu, phorbol 
12,13-dibutyrate; PMA, phorbol-12-myristate-13-acetate; T3, l-3,3′,5-Triiodothyronine; TPB, [(2S,5S)-(E,E)-8-(5-(4-(trifluoromethyl)phenyl)-2,4-pentadienoylamino) benzolactam].
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lipid-soluble vitamin A derivative synthesized from the oxida-
tion of retinaldehyde via enzymes retinaldehyde dehydrogenase 
1 (RALDH1), RALDH2, and RALDH3. RA produced at the 
splanchnic lateral plate mesoderm and Raldh2 expressed in 
the dorsal pancreatic mesenchyme promote Pdx1 induction in 
the dorsal foregut endoderm (Figure 1A). Raldh2 mutant mice 
exhibit dorsal pancreatic bud agenesis (29) as they fail to form 
pancreatic progenitors, indicated by the loss of Pdx1, Prox1, 
altered Isl1, and reduced Hlxb9 expression (29, 30).
Many existing protocols differentiating hPSCs into pancreatic 
cells utilize 1–3 μM RA. As an alternative, Schulz et al. replaced 
RA with 3 nM TTNPB/arotinoid acid – a more stable retinoid 
analog that can selectively activate RA receptors (RARs) (17). 
Interestingly, Rezania et  al. started out using 1 μM RA during 
the early posterior foregut differentiation, subsequently reducing 
to 100 nM RA during pancreatic endoderm phase and further 
reducing to 50  nM during the pancreatic endocrine phase (6). 
Pagliuca et al. also reported a similar pancreatic differentiation 
protocol in which a decreasing dose of RA was used, starting with 
2 μM followed by 100 nM RA at later stages, which was eventually 
reduced to 25 nM (7) (Figure 1B; Table 1).
While it is widely accepted that RA is crucial for pancreatic 
specification, using progressively lower doses of RA as prac-
ticed by Rezania et al. (6) and Pagliuca et al. (7) raises questions 
about the importance of RA concentrations during pancreas 
development both in vitro and in vivo. RA signals by binding 
RARs and retinoid X receptors (RXRs); so it is postulated that a 
decrease in RA signaling may be more conducive for subsequent 
pancreatic endocrine specification since retinoid receptors are 
upregulated in the pancreatic exocrine (31). However, given the 
lack of understanding in this regard, the significance of the dose 
of RA during human pancreas development warrants further 
studies.
inHiBiTinG γ-SeCReTASe/nOTCH FOR 
ACCeLeRATeD PAnCReATiC 
enDOCRine DiFFeRenTiATiOn
Notch signaling is essential for the proper development of 
pancreatic endocrine progenitors as it regulates their decision 
between differentiation and proliferation (32). The reduction 
of Notch signaling is known to promote accelerated pancreatic 
endocrine differentiation (33). Similarly, the inhibition of Notch 
signaling via γ-secretase (an intra-membrane protease) inhibitor 
can downregulate the expression of Notch target Hes-1, an inhibi-
tor of pro-endocrine gene Ngn3 (34) (Figure  1A). Conversely, 
the activation of Notch in PDX1+ pancreatic progenitors prevents 
pancreatic differentiation (35).
N-[N-(3,5-difluorophenacetyl-l-alanyl)]-S-phenylglycine 
t-butyl ester (DAPT) is a commonly used γ-secretase inhibi-
tor with an IC50 in the nM range. The inhibition of Notch 
signaling with DAPT can increase Ngn3 mRNA and protein 
expression in adult islets (36). Likewise, DAPT increases NGN3 
and NEUROD1 gene expression in hPSC-derived pancreatic 
progenitors (18). In recent protocols developed by Pagliuca 
et al. (7) and Rezania et al. (6), other γ-secretase inhibitors have 
been employed to retard Notch signaling. Rezania et  al. used 
γ-secretase inhibitor XX (GSiXX) that has an IC50 in the low 
nM range. They showed that GSiXX can induce the expression 
of β cell maturation genes but inhibit the expression of PTF1A, a 
marker of pancreatic exocrine lineage (6). GSiXX can also act in 
concert with triiodothyronine (T3) to increase the percentage of 
NKX6.1+INS+GCG− β-like cells (6). Alternatively, Pagliuca et al. 
employed the use of XXI at 1 μM (7), which has an IC50 in the 
picomolar range, and demonstrated that XXI worked with other 
factors to improve β cell gene expression (Figure 1B; Table 1). 
However, it remains unclear whether there are differences 
between DAPT, GSIXX, or XXI in the induction or suppression 
of key pancreatic transcription factors for the eventual promo-
tion of pancreatic β cell formation.
TRiiODOTHYROnine COULD PROMOTe 
PAnCReATiC β CeLL MATURATiOn
Studies in the 1980s suggest that thyroid hormones regulate 
insulin secretion, possibly via control over glucose oxidation and 
calcium uptake rates (37). T3, a thyroid hormone, can potenti-
ate insulin signaling and increase insulin synthesis in diabetic 
rodents (38), in rodent islets (39), and in a rodent pancreatic β cell 
line (40) (Figure  1A). Mechanistically, T3 phosphorylates and 
activates AKT in pancreatic β cells, improving their survival (39, 
41); 0.1 μM of T3 can increase rodent pancreatic β cell prolifera-
tion via the MAPK/extracellular signal-regulated kinase (ERK) 
signaling pathway (42). Interestingly, T3 apparently induces 
the transdifferentiation of human pancreatic ductal cell line 
(hPANC-1) into β-like cells, with an increased expression of INS 
transcripts (43). T3 can also increase both the mRNA expression 
of pro-endocrine gene Ngn3 and the number of β cells, indirectly 
inducing endocrine differentiation from exocrine cells; possibly 
via Akt signaling (44).
Of late, T3 has been shown to promote pancreatic β cell 
maturation and proliferation in rats (45). Based on these findings, 
Rezania et al. went on to demonstrate that 1 μM of T3 can actu-
ally induce the expression of INS and mature β cell markers, and 
enhance the co-expression of NKX6.1 and INSULIN protein (6). 
Similarly, Pagliuca et al. employed the same dose of 1 μM T3 in the 
later stages of their pancreatic differentiation protocol to generate 
human pancreatic β cells from hPSCs (7) (Figure 1B; Table 1). 
While the biology and role of T3 in pancreatic β cell maturation 
remains to be explored further, its inclusion in pancreatic dif-
ferentiation protocols appears to serve a positive function.
inHiBiTiOn OF TYROSine KinASe 
ReCePTOR AXL inDUCeS MATURe 
PAnCReATiC β CeLL MARKeR (MAFA) 
eXPReSSiOn
AXL is a member of the Tyro3-Axl-Mer (TAM) trans-
membrane receptor tyrosine kinase (RTK) family that plays 
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an important role in essential cellular processes, such as cell 
survival, growth, proliferation, and differentiation. Its ligand, 
growth arrest specific 6 (Gas6), binds AXL to activate down-
stream signaling, including the phosphoinositide 3-kinase 
(PI3K), ERK, and signal transducer and activator of transcrip-
tion 3 (STAT3) signaling (46). Interestingly, Rezania et  al. 
performed small molecule and growth factor library screening 
to identify compounds that can induce mature β cell marker 
MAFA from hPSC-derived pancreatic progenitors and found 
that 2 μM BGB324 (R428), an inhibitor of AXL, can induce 
MAFA protein expression (6) (Figure 1B; Table 1). However, 
there is little information linking AXL to pancreas develop-
ment and β cell maturation.
In 1999, Augustine et al. reported that the overexpression of 
AXL results in diabetes in mice. Furthermore, the administra-
tion of exogenous Gas6 exacerbated the condition (47). Haase 
et  al. recently confirmed that GAS6 is expressed in pancreatic 
tissues and found that GAS6 reduced Mafa gene expression in 
rodents (48), likely due to the activation of AXL (Figure 1A). This 
corresponds with the increase in MAFA expression observed by 
Rezania et  al. after the inhibition of AXL signaling (6). While 
there seems to be a bona fide association between AXL signaling 
and pancreas development, the cellular mechanism(s) remain a 
mystery.
AnTiOXiDAnTS MAY BeneFiT 
PAnCReATiC DiFFeRenTiATiOn
Excessive levels of reactive oxygen species (ROS) have 
been implicated in glucotoxicity-induced pancreatic β cell 
destruction and dysfunction. In this regard, antioxidants 
play important defensive roles against ROS. In the endocrine 
pancreas, the antioxidant vitamin C is known to be an effective 
co-factor for the peptidyl α-amidation of several biologically 
active peptides and is necessary for optimal insulin secretion 
from pancreatic β cells (Figure 1A). In fact, high concentra-
tions of ascorbic acid (vitamin C) were found in neonatal 
rat endocrine pancreas (49). Mechanistic studies involving 
other antioxidants, such as glutathione peroxidase-1 (GPx-1), 
N-acetylcysteine (NAC), and ebselen, were reported to main-
tain the protein expression of mature β cell marker MAFA 
(20–22) (Table 1).
Interestingly, Rezania et al. used 1–2 mM NAC during their 
pancreatic differentiation and found that it also increased nuclear 
MAFA protein expression (6). However, this was not replicated 
with another antioxidant, vitamin E. Pagliuca et  al. also relied 
upon the use of 0.25 mM of vitamin C throughout S1–S5 phase of 
their pancreatic differentiation protocol to generate mature and 
functional human pancreatic β cells (7) (Figure  1B; Table  1). 
While the metabolism of vitamins C and E are altered before 
the onset of diabetes in rats, their contribution to the pancreas 
is unclear (50). Antioxidant treatments may preserve β cell func-
tion, exerting positive effects in diabetes (51), but their role in 
pancreas development and β cell maturation certainly remains 
elusive.
BeTACeLLULin DiReCTS A PAnCReATiC 
β CeLL FATe
Betacellulin (BTC) is a member of the epidermal growth factor 
(EGF) family that plays a role in the differentiation of pancreatic 
β cells (52) (Figure 1A). It is largely expressed in the liver, kidney, 
small intestine, and pancreas (53), and is specifically expressed 
in 9- to 24-week-old human fetal pancreas (54). BTC binds to 
ErbB-1 and ErbB-4 receptors (55) to initiate downstream sign-
aling pathways involving PI3K/Akt, MAPK, STAT, and mTOR 
signaling pathways (56).
Betacellulin appears to direct a pancreatic β cell fate. It can con-
vert exocrine cells (57) and α cells (58) into insulin-secreting cells. 
It can also induce β cell neogenesis from ductal cells in diabetic 
mice (59). Li et al. demonstrated that exogenous BTC can promote 
β cell regeneration in 90% pancreatectomized rats (60) and convert 
δ to β cells in STZ-induced diabetic mice (61). Also, Yamamoto 
et  al. observed that long-term administration of BTC reverses 
STZ-induced hyperglycemia in mice (62). Surprisingly, the loss of 
BTC in mice yielded no overt defect (63) despite their active roles 
in the pancreas. This could be explained by compensatory effects 
exhibited by the other EGFR ligands (64). The overexpression of 
BTC in transgenic islets does not affect islet structure, endocrine 
cell ratio, or β cell mass but enhances glucose-stimulated insulin 
secretion (65). However, ubiquitous overexpression of BTC in 
mice results in various pathologies (66). Intriguingly, gene vari-
ants and polymorphisms in the BTC gene have also been found to 
be associated with types 1 and 2 diabetes (54, 67).
The induction of β cell development/differentiation by BTC (52) 
could be an outcome of the downstream increase in insulin recep-
tor substrate-2 (IRS-2) expression (68), an important mediator of 
β cell function (69). BTC can induce Pax4 gene expression in rat 
islets, promoting β cell functionality (70). It can also sustain PDX1 
expression and induce β cell differentiation from hPSCs (71). Ten 
ng/ml BTC are sufficient to increase Pdx1 gene expression, insulin 
production, and to inhibit amylase and glucagon production in 
mouse embryonic pancreas explants (72). Lately, Pagliuca et  al. 
employed 20  ng/ml BTC in the later stages of their pancreatic 
differentiation protocol (7). Similarly, 50 ng/ml EGF was added to 
preserve cell mass (17) (Figure 1B; Table 1). These data strongly 
indicate that BTC and/or other EGF ligands are of importance in 
pancreas development and β cell maturation. Nonetheless, more 
detailed molecular mechanisms remain to be uncovered.
COnCLUDinG ReMARKS
Relating to the current most advanced human pancreatic β cell 
differentiation protocols, the biological mechanisms involved in 
the later stages of β cell development and maturation still remain 
elusive. The fact that the postnatal stage in rodents is grossly 
equivalent to the third trimester in human pancreas development 
(73) invites new approaches to study this aspect of β cell biology. 
In this review, we revisited some of the least-understood devel-
opmental signaling pathways in rodent pancreas biology. Our 
efforts unraveled interesting aspects of these signaling pathways 
that demand to be thoroughly elucidated at the mechanistic level. 
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Future studies should seek to highlight how immature β cells 
transit into mature and functional β cells. This would certainly 
advance our knowledge of human pancreas developmental biol-
ogy and boost translational efforts in the use of stem cells for 
diabetes treatment.
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